Sanofi, Lonza JV Should Offer Pair Flexibility In Biologics Manufacturing
The pair's pact to build a biologics manufacturing site in Switzerland will allow Sanofi to expand or contract capacity usage in response to demand for its future biological therapies and give Lonza the option to pick up any eventual slack.
You may also be interested in...
Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.
Elias Zerhouni says Sanofi's ongoing R&D revamp has produced improved innovative results with controlled spending, in part by emphasizing cutting-edge product development ahead of research.
Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.